Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
화요일, 9월 01

Clover Health Investments Corp

CLOVNASDAQ
Trade with Public
Trade with Public
$4.30
0.153.61%
가까이에: Sep 1, 5:00 PM EST
$4.28
-0.0195-0.45%
시간외: 7:19 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Clover Health Investments Analyst Price Targets

Wall Street analyst price targets and consensus rating for Clover Health Investments (CLOV).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT+11.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026UBSJonathan YongPT RaiseNeutral$5→$5
Jul 21, 2026Canaccord GenuityRichard ClosePT RaiseBuy$4→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.
Benzinga Newsdesk

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $2.75 to $4.75.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and maintains $3.7 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved